35Pharma
QC - MontrealPharmaceutical
Focus: 35Pharma is a Montreal-based biotech focused on ligand trap technology for rare diseases with high unmet medical need, particularly pulmonary arterial hypertension. The company was acquired by GSK for $950 million in April 2026, indicating validation of its platform and pipeline.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES C +
Total Funding
$300M
Open Jobs
0
About 35Pharma
AI assessmentNot HiringNo open roles listed right now. Follow 35Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 1
Clinical Trials (2)
NCT06581159Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Phase 1Help build intelligence for 35Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.